Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

HHS Import Report Gives No Ground: Savings Would Not Exceed 1%

This article was originally published in The Pink Sheet Daily

Executive Summary

Drug Importation Task Force Report suggests a limited, tightly regulated commercial import system is "feasible," but only if policymakers accept minimal savings and possible consequences on drug development. Report does not quantify costs of creating import system, but veto threat is explicit.

You may also be interested in...



Importation, Internet Pharmacy Slated For Senate Aging Cmte. Hearing Jan. 26

Committee's first hearing under Chairman Gordon Smith (R-Ore.) will focus on risk/benefit issues with importation. Canada-only imports and the Bush Administration's recent task force report are among the likely topics.

Importation, Internet Pharmacy Slated For Senate Aging Cmte. Hearing Jan. 26

Committee's first hearing under Chairman Gordon Smith (R-Ore.) will focus on risk/benefit issues with importation. Canada-only imports and the Bush Administration's recent task force report are among the likely topics.

HHS Nominee Leavitt Wants To "Learn More" About Rx Imports

Michael Leavitt tells Senate Finance Committee during confirmation hearing that he has read "conflicting views" on the economic benefits of drug importation. Leavitt also notes that as HHS Secretary, importation safety issues would fall "squarely" on his desk.

Related Content

Topics

UsernamePublicRestriction

Register

MT142539

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel